Differential regulation of neurotrophin S100B and BDNF in two rat models of depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1433-1439

  Luo, Kai Ren ^a   Hong, Chen Jee ^a,b   Liou, Ying Jay ^a,b   Hou, Sheue Jane ^c   Huang, Yn Ho ^a   Tsai, Shih Jen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

Author keywords

Brain derived neurotrophic factor; Chronic unpredictable mild stress; Depressive disorders; Olfactory bulbectomy; S100B

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PROTEIN S100B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CHRONIC STRESS; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; OLFACTORY BULBECTOMY; PREFRONTAL CORTEX; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; NERVE GROWTH FACTORS; OLFACTORY BULB; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY; S100 PROTEINS; STRESS, PSYCHOLOGICAL;

EID: 78649494322     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.033     Document Type: Article

References (41)

1. Arolt V., Peters M., Erfurth A., Wiesmann M., Missler U., Rudolf S., et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003, 13:235-239.
2. Banasr M., Valentine G.W., Li X.Y., Gourley S.L., Taylor J.R., Duman R.S. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry 2007, 62:496-504.
3. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
4. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
5. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
6. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60:540-551.
7. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
8. Elfving B., Plougmann P.H., Müller H.K., Mathé A.A., Rosenberg R., Wegener G. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010, 13:563-572.
9. Govindarajan A., Rao B.S., Nair D., Trinh M., Mawjee N., Tonegawa S., et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 2006, 103:13208-13213.
10. Grabe H.J., Ahrens N., Rose H.J., Kessler C., Freyberger H.J. Neurotrophic factor S100 beta in major depression. Neuropsychobiology 2001, 44:88-90.
11. Grønli J., Bramham C., Murison R., Kanhema T., Fiske E., Bjorvatn B., et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacol Biochem Behav 2006, 85:842-849.
12. Groves J.O. Is it time to reassess the BDNF hypothesis of depression?. Mol Psychiatry 2007, 12:1079-1088.
13. Hellweg R., Zueger M., Fink K., Hörtnagl H., Gass P. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis 2007, 25:1-7.
14. Holmes P.V., Davis R.C., Masini C.V., Primeaux S.D. Effects of olfactory bulbectomy on neuropeptide gene expression in the rat olfactory/limbic system. Neuroscience 1998, 86:587-596.
15. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
16. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002, 328:261-264.
17. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072.
18. Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005, 136:29-37.
19. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997, 74:299-316.
20. Lumia A.R., Teicher M.H., Salchli F., Ayers E., Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 1992, 587:181-185.
21. Mar A., Spreekmeester E., Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology 2000, 150:52-60.
22. McArthur R., Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 2006, 84:436-452.
23. Missler U., Wiesmann M. Measurement of S-100 protein in human blood and cerebrospinal fluid: analytical method and preliminary clinical results. Eur J Clin Chem Clin Biochem 1995, 33:743-748.
24. Molnar M., Potkin S.G., Bunney W.E., Jones E.G. MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. Biol Psychiatry 2003, 53:39-47.
25. Nishi M., Kawata M., Azmitia E.C. Trophic interactions between brain-derived neurotrophic factor and s100beta on cultured serotonergic neurons. Brain Res 2000, 868:113-118.
26. Regner A., Kaufman M., Friedman G., Chemale I. Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death?. NeuroReport 2001, 12:691-694.
27. Rothermundt M., Arolt V., Wiesmann M., Missler U., Peters M., Rudolf S., et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001, 66:89-93.
28. Rothermundt M., Peters M., Prehn J.H., Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003, 60:614-632.
29. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
30. Schroeter M.L., Abdul-Khaliq H., Diefenbacher A., Blasig I.E. S100B is increased in mood disorders and may be reduced by antidepressive treatment. NeuroReport 2002, 13:1675-1678.
31. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008, 111:271-280.
32. Schulte-Herbrüggen O., Chourbaji S., Müller H., Danker-Hopfe H., Brandwein C., Gass P., et al. Differential regulation of nerve growth factor and brain-derived neurotrophic factor in a mouse model of learned helplessness. Exp Neurol 2006, 202:404-409.
33. Schulte-Herbrüggen O., Hörtnagl H., Ponath G., Rothermundt M., Hellweg R. Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci Lett 2008, 442:100-103.
34. Sen J., Belli A. S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res 2007, 85:1373-1380.
35. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
36. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003, 54:70-75.
37. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29:627-647.
38. Tsai S.J. Down-regulation of the Trk-B signal pathway: the possible pathogenesis of major depression. Med Hypotheses 2004, 62:215-218.
39. Vitale G., Ruggieri V., Filaferro M., Frigeri C., Alboni S., Tascedda F., et al. Chronic treatment with the selective NOP receptor antagonist [Nphe(1), Arg (14), Lys (15)]N/OFQ-NH (2) (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology 2009, 207:173-189.
40. Whitaker-Azmitia P.M., Murphy R., Azmitia E.C. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990, 528:155-158.
41. Yang K., Xie G.R., Hu Y.Q., Mao F.Q., Su L.Y. The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm 2008, 115:1687-1694.